Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

PURPOSE: Carfilzomib, a selective proteasome inhibitor, has demonstrated safety and efficacy in relapsed and/or refractory multiple myeloma. This Phase I study in patients with relapsed or progressive multiple myeloma assessed the safety and tolerability of escalating doses of carfilzomib in combina...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Niesvizky, Ruben, Martin, Thomas G., Bensinger, William I., Alsina, Melissa, Siegel, David S., Kunkel, Lori A., Wong, Alvin F., Lee, Susan, Orlowski, Robert Z., Wang, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4149337/
https://ncbi.nlm.nih.gov/pubmed/23447001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3352
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados